Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
Recursion could receive over $300 million in additional milestone payments from the program. ・Sanofi will fund the development of the drug, with Phase 1 clinical trials expected to begin in 2027.
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other ...
Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Recursion Pharmaceuticals (RXRX) held about $557 million in cash at the end of its second quarter of 2026. Investors should ...
Tech Times on MSN
Chinese AI model helps prove 31-year-old math conjecture with machine-verified Lean proof
Chinese AI math proof reaches a new milestone: Shanghai AI Lab's Shusheng-S2 helped resolve the 31-year-old Ghys conjecture, ...
Recursion Pharmaceuticals announced a $10 million milestone payment from Sanofi for a new drug candidate targeting ...
As AI companies warn of the dangers of self-improving AI, a new report offers a rare look at how they’re working to make it a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results